Imatinib Aqvida (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, blocking their activity. This inhibition stops downstream signaling that promotes cell proliferation and survival, leading to reduced tumor growth and induction of apoptosis in malignant cells.

The exact dose of Imatinib Aqvida is determined by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other individual factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic benefit while minimizing risk.

Safety data for Imatinib in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and risk assessment with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor approved and remains a standard of care for CML and Ph+ ALL. Compared with newer agents, it has a well‑characterized safety profile and extensive clinical experience, though some newer inhibitors may offer activity against certain resistant mutations. Choice of therapy depends on disease characteristics and physician judgment.

Imatinib Aqvida should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Imatinib Aqvida is taken orally, usually with a glass of water. It can be swallowed with or without food, but patients should follow the specific instructions provided by their prescriber to maintain consistent absorption and therapeutic effect.

Serious risks include severe neutropenia or leukopenia, hepatotoxicity, cardiac dysfunction such as reduced ejection fraction, pulmonary hypertension, and rare but life‑threatening allergic reactions. Patients should be monitored regularly for these events and report any concerning symptoms promptly.

Imatinib Aqvida is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those receiving strong CYP3A4 inducers or inhibitors without appropriate monitoring.